Apogee Acquisition 3Q 2026: Net income $1.44M — 10-Q Summary

Apogee Acquisition reported a net income of $1.44M for 3Q 2026, driven by investment income and offset by expenses. The company has no revenue and is seeking a business combination. It held $176.3M in trust and $286,457 in cash outside the trust. Management expressed doubt about its ability to continue as a going concern.

Original reporting
Published Nov 13, 2026, 10:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 10:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Apogee Acquisition 3Q 2026: Net income $1.44M — 10-Q Summary — source image
Decision brief

The 30-second read

$AACPNeutralLow
01

Why it matters

The filing provides the first public numbers for the quarter, showing a small net profit from investment income but raising concerns about liquidity and going‑concern status.

02

Market read

Limited relevance; primarily of interest to SPAC investors monitoring deadline and cash position.

03

What to watch

Trust account size could fund a future acquisition, but cash outside trust is limited.

Relevance 4/10Novelty 3/10Timing: post‑market filing today

Background

Apogee Acquisition Corp is a SPAC that has not yet completed a business combination and is filing its 10‑Q for Q3 2026.

Company-level read

Ticker impact

$AACPNeutralMedium confidence
Context

10-Q filing reports $1.44M net income and $176.3M trust balance for Apogee Acquisition.

Expected impact

limited pressure as investors assess SPAC viability and deadline.

Evidence & confidence

Micro‑cap SPAC with modest earnings and cash concerns; unlikely to move price significantly.

Market effects

Minimal impact on broader SPAC market; reflects typical early‑stage filing.

None

None

Counterpoint

Potential upside if a suitable target is found before deadline.

Key entities

  • Apogee Acquisition Corp

    SPAC filing 10‑Q, ticker AACP.

Related articles

$SBCHigh

Why SBC Medical Stock Skyrocketed on Friday

SBC Medical Group (NASDAQ:SBC) shares rose 37% after reporting Q3 revenue of $59M, up 35% YoY, and announcing an AI partnership with NeuroBrain Dynamics. The company added 36 clinics, increasing total locations to 293, and saw a 9% rise in patient visits. Operating income surged 66% to $26M, with a 45% operating margin.

$BTOMedAI 8/10

B2Gold Earnings Call Signals Lower Costs and Growth

B2Gold Corp. reported Q3 earnings with strong production, lower cost guidance, and positive free cash flow. The company produced 193,000 ounces of gold, reduced all-in sustaining cost guidance by over $100 per ounce, and generated $48 million in free cash flow. Revenue reached $836 million, supported by higher gold prices. The company also highlighted growth projects and shareholder returns.

$NMAXMed

Why Newsmax Stock Popped on Friday

Newsmax (NMAX) shares rose 31% after reporting Q3 revenue of $69M, up 52.5% YoY, and net income of $15.2M. The company cited strong audience engagement and growth in high-margin revenue streams. CEO Christopher Ruddy expects continued growth ahead of the presidential election.

$LUNRMed

What Is Driving Intuitive Machines Stock?

Intuitive Machines (LUNR) shares rose 7.0% on Nov 12, 2026, after reporting Q3 revenue of $269M, beating estimates. The company's loss of $0.10 per share met expectations, while gross margin improved to 26%. Free cash flow turned positive at $33M, a company record. Management raised full-year revenue guidance to $920M-$950M. The stock's performance contrasted with broader industry declines.

$RMIXMedAI 8/10

Suncrete (RMIX) Q3 2026 Earnings Call Transcript

Suncrete (RMIX) reported Q3 2026 revenue of $141M, up 45% QoQ and 163% YoY. Adjusted EBITDA rose 66% QoQ to $22.4M. The company lowered its full-year outlook due to residential construction weakness but remains confident in long-term demand. Acquisition integration is progressing, with North Texas showing margin improvement. Suncrete expects $200M-$250M revenue from 2026 acquisitions in 2027. The company has $206.5M in total liquidity.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.